UBS O'Connor’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-34,788
| Closed | -$31.7K | – | 349 |
|
|
2025
Q1 | $31.7K | Sell |
34,788
-166,444
| -83% | -$151K | ﹤0.01% | 241 |
|
|
2024
Q4 | $557K | Sell |
201,232
-25,000
| -11% | -$69.3K | 0.01% | 263 |
|
|
2024
Q3 | $1.18M | Buy |
226,232
+21,014
| +10% | +$110K | 0.03% | 253 |
|
|
2024
Q2 | $915K | Buy |
205,218
+22,000
| +12% | +$98.1K | 0.03% | 303 |
|
|
2024
Q1 | $1.4M | Sell |
183,218
-61,710
| -25% | -$473K | 0.04% | 237 |
|
|
2023
Q4 | $1.04M | Buy |
244,928
+89,623
| +58% | +$382K | 0.03% | 260 |
|
|
2023
Q3 | $652K | Hold |
155,305
| – | – | 0.01% | 358 |
|
|
2023
Q2 | $865K | Buy |
155,305
+7,651
| +5% | +$42.6K | 0.02% | 393 |
|
|
2023
Q1 | $846K | Buy |
+147,654
| New | +$846K | 0.02% | 420 |
|
|
2022
Q4 | – | Sell |
-165,498
| Closed | -$444K | – | 155 |
|
|
2022
Q3 | $444K | Sell |
165,498
-5,849
| -3% | -$15.7K | 0.01% | 794 |
|
|
2022
Q2 | $817K | Buy |
+171,347
| New | +$817K | 0.01% | 772 |
|